arrow
D

David H. Munn

Augusta University
H指数:96
被引数:4.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Robust activation and clonal expansion of early, non-exhausted, stem-like endogenous T cells induced by chemo-immunotherapy treatment in patients with pediatric brain tumors is predictive of clinical outcome

在儿科脑肿瘤患者中,由化疗免疫疗法治疗诱导的早期、非耗竭、干细胞样内源T细胞的稳健激活和克隆扩增,可预测临床结局。

2025-11-010
OAAI
UFL1 promotes survival and function of virtual memory CD8 T cells

UFL1促进虚拟记忆CD8 T细胞的存活和功能

2025-02-240
PRE
PHASE 2 TRIAL USING INDOXIMOD-BASED CHEMO-IMMUNOTHERAPY FOR PATIENTS WITH CHILDHOOD BRAIN CANCER: INTERIM ANALYSIS OF THE GCC1949 STUDY (NCT04049669)
2024-06-180
OAAI
Indoximod-based chemo-immunotherapy for pediatric brain tumors: A first-in-children phase I trial
2023-09-1611
OAAI
INTERIM ANALYSIS OF THE GCC1949 PHASE 2 TRIAL USING INDOXIMOD-BASED CHEMO-IMMUNOTHERAPY FOR PATIENTS WITH PEDIATRIC BRAIN TUMORS
2023-06-120
OAAI
Inhibition of the BTK-IDO-mTOR axis promotes differentiation of monocyte-lineage dendritic cells and enhances anti-tumor T cell immunity
IMMUNITY
IF26.3
2021-10-0153
OA
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma
2021-06-1154
OAAI
FIRST-IN-CHILDREN PHASE 1B STUDY USING THE IDO PATHWAY INHIBITOR INDOXIMOD IN COMBINATION WITH RADIATION AND CHEMOTHERAPY FOR CHILDREN WITH NEWLY DIAGNOSED DIPG (NCT02502708, NLG2105)
2021-06-012
OA